Quince Therapeutics Statistics Share Statistics Quince Therapeutics has 53.71M
shares outstanding. The number of shares has increased by 5.07%
in one year.
Shares Outstanding 53.71M Shares Change (YoY) 5.07% Shares Change (QoQ) 3.33% Owned by Institutions (%) n/a Shares Floating 41.11M Failed to Deliver (FTD) Shares 5,765 FTD / Avg. Volume 2.4%
Short Selling Information The latest short interest is 929.12K, so 1.73% of the outstanding
shares have been sold short.
Short Interest 929.12K Short % of Shares Out 1.73% Short % of Float 1.94% Short Ratio (days to cover) 3.56
Valuation Ratios The PE ratio is -1.42 and the forward
PE ratio is -2.21.
Quince Therapeutics's PEG ratio is
-0.03.
PE Ratio -1.42 Forward PE -2.21 PS Ratio 0 Forward PS n/a PB Ratio 2.68 P/FCF Ratio -2.52 PEG Ratio -0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Quince Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.05,
with a Debt / Equity ratio of 0.49.
Current Ratio 6.05 Quick Ratio 6.05 Debt / Equity 0.49 Debt / EBITDA -0.26 Debt / FCF -0.46 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.58M Employee Count 36 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 87K Effective Tax Rate -0.15%
Stock Price Statistics The stock price has increased by 131.51% in the
last 52 weeks. The beta is 1, so Quince Therapeutics's
price volatility has been higher than the market average.
Beta 1 52-Week Price Change 131.51% 50-Day Moving Average 1.68 200-Day Moving Average 1.5 Relative Strength Index (RSI) 48.56 Average Volume (20 Days) 239,962
Income Statement
Revenue n/a Gross Profit -186K Operating Income -57.28M Net Income -56.83M EBITDA -56.55M EBIT -56.74M Earnings Per Share (EPS) -1.31
Full Income Statement Balance Sheet The company has 6.21M in cash and 14.81M in
debt, giving a net cash position of -8.6M.
Cash & Cash Equivalents 6.21M Total Debt 14.81M Net Cash -8.6M Retained Earnings -376.47M Total Assets 117.21M Working Capital 29.88M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -31.9M
and capital expenditures -257K, giving a free cash flow of -32.16M.
Operating Cash Flow -31.9M Capital Expenditures -257K Free Cash Flow -32.16M FCF Per Share -0.74
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
